Literature DB >> 21593107

18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism.

Yasuhiro Nakamura1, Fumitoshi Satoh, Ryo Morimoto, Masataka Kudo, Kei Takase, Celso E Gomez-Sanchez, Seijiro Honma, Mitsunobu Okuyama, Kouwa Yamashita, William E Rainey, Hironobu Sasano, Sadayoshi Ito.   

Abstract

CONTEXT: 18-Oxocortisol (18-oxoF) is a derivative of cortisol (F) that is produced by aldosterone synthase (CYP11B2). The potential for this steroid as a biomarker for differentiating patients with aldosterone-producing adenoma (APA) from those with idiopathic hyperaldosteronism (IHA) has not been examined.
OBJECTIVES: We measured 18-oxoF, aldosterone, and F in plasma from adrenal vein sampling (AVS) of patients with primary aldosteronism. We compared 18-oxoF levels and 18-oxoF/F ratios for their potential to differentiate APA from IHA. DESIGN, SETTING, AND
SUBJECTS: This study measured 18-oxoF, F, and aldosterone in AVS obtained from patients with unilateral APA (14 cases) or bilateral IHA (seven cases, 14 samples total) using liquid chromatography-tandem mass spectrometry and RIA analyses.
RESULTS: The levels of 18-oxoF and the ratios of 18-oxoF/F, before and after ACTH stimulation, were significantly higher in blood-draining APA than in those from the contralateral adrenal glands and from adrenal glands with IHA.
CONCLUSIONS: The 18-oxoF levels and ratios of 18-oxoF/F in AVS samples can be a clinically useful biomarker for differentiating APA from IHA and for determining the localization or lateralization of APA in patients with primary aldosteronism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593107      PMCID: PMC5393430          DOI: 10.1210/jc.2010-2785

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients.

Authors:  Gian Paolo Rossi; Chiara Ganzaroli; Diego Miotto; Renzo De Toni; Gaetana Palumbo; Gian Pietro Feltrin; Franco Mantero; Achille C Pessina
Journal:  J Hypertens       Date:  2006-02       Impact factor: 4.844

2.  Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study.

Authors:  Gilberta Giacchetti; Vanessa Ronconi; Federica Turchi; Laura Agostinelli; Franco Mantero; Silvia Rilli; Marco Boscaro
Journal:  J Hypertens       Date:  2007-01       Impact factor: 4.844

3.  Effects of 18-hydroxylated steroids on corticosteroid production by human aldosterone synthase and 11beta-hydroxylase.

Authors:  A Fisher; E C Friel; R Bernhardt; C Gomez-Sanchez; J M Connell; R Fraser; E Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

4.  CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism.

Authors:  P Mulatero; D Schiavone; F Fallo; F Rabbia; C Pilon; L Chiandussi; L Pascoe; F Veglio
Journal:  Hypertension       Date:  2000-03       Impact factor: 10.190

Review 5.  Genetic approaches to understanding the pathophysiology of complex human traits.

Authors:  G H Williams
Journal:  Kidney Int       Date:  1994-12       Impact factor: 10.612

6.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  Use of novel picolinoyl derivatization for simultaneous quantification of six corticosteroids by liquid chromatography-electrospray ionization tandem mass spectrometry.

Authors:  Kouwa Yamashita; Madoka Takahashi; Satoshi Tsukamoto; Mitsuteru Numazawa; Mitsunobu Okuyama; Seijiro Honma
Journal:  J Chromatogr A       Date:  2007-10-12       Impact factor: 4.759

8.  Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols.

Authors:  Teresa M Seccia; Diego Miotto; Renzo De Toni; Gisella Pitter; Franco Mantero; Achille C Pessina; Gian Paolo Rossi
Journal:  Hypertension       Date:  2009-04-06       Impact factor: 10.190

9.  Localization of aldosterone-producing adrenocortical adenomas: significance of adrenal venous sampling.

Authors:  Fumitoshi Satoh; Takaaki Abe; Masayuki Tanemoto; Masahiro Nakamura; Michiaki Abe; Akira Uruno; Ryo Morimoto; Akihiro Sato; Kei Takase; Shigeto Ishidoya; Yoichi Arai; Takashi Suzuki; Hironobu Sasano; Tadashi Ishibashi; Sadayoshi Ito
Journal:  Hypertens Res       Date:  2007-11       Impact factor: 3.872

10.  Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension.

Authors:  S Ulick; M D Chu
Journal:  Clin Exp Hypertens A       Date:  1982
View more
  25 in total

Review 1.  Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review.

Authors:  Lina Schiffer; Lise Barnard; Elizabeth S Baranowski; Lorna C Gilligan; Angela E Taylor; Wiebke Arlt; Cedric H L Shackleton; Karl-Heinz Storbeck
Journal:  J Steroid Biochem Mol Biol       Date:  2019-07-27       Impact factor: 4.292

2.  PCP4: a regulator of aldosterone synthesis in human adrenocortical tissues.

Authors:  Saulo J A Felizola; Yasuhiro Nakamura; Yoshikiyo Ono; Kanako Kitamura; Kumi Kikuchi; Yoshiaki Onodera; Kazue Ise; Kei Takase; Akira Sugawara; Namita Hattangady; William E Rainey; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Mol Endocrinol       Date:  2014-02-24       Impact factor: 5.098

3.  Diagnosis: 18-Oxocortisol-a biomarker in adrenal vein sampling.

Authors:  Carol Wilson
Journal:  Nat Rev Endocrinol       Date:  2011-06-21       Impact factor: 43.330

Review 4.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 5.  Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.

Authors:  Finn Holler; Daniel A Heinrich; Christian Adolf; Benjamin Lechner; Martin Bidlingmaier; Graeme Eisenhofer; Tracy Ann Williams; Martin Reincke
Journal:  Curr Hypertens Rep       Date:  2019-09-03       Impact factor: 5.369

6.  Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Elise P Gomez-Sanchez; Hironobu Sasano; Martin O Bohlen; Max Wisgerhof
Journal:  Mol Cell Endocrinol       Date:  2016-10-25       Impact factor: 4.102

7.  A marked proportional rise in IVC aldosterone following cosyntropin administration during AVS is a signal to the presence of adrenal hyperplasia in primary aldosteronism.

Authors:  G A Kline; J L Pasieka; A Harvey; B So; V C Dias
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

Review 8.  DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

Authors:  Jacques W M Lenders; Tracy Ann Williams; Martin Reincke; Celso E Gomez-Sanchez
Journal:  Eur J Endocrinol       Date:  2017-09-13       Impact factor: 6.664

9.  Angiotensin II triggers expression of the adrenal gland zona glomerulosa-specific 3β-hydroxysteroid dehydrogenase isoenzyme through de novo protein synthesis of the orphan nuclear receptors NGFIB and NURR1.

Authors:  Takumi Ota; Masao Doi; Fumiyoshi Yamazaki; Daisuke Yarimizu; Kazuki Okada; Iori Murai; Hida Hayashi; Sumihiro Kunisue; Yuuki Nakagawa; Hitoshi Okamura
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

Review 10.  Mass spectrometry theory and application to adrenal diseases.

Authors:  Kerry M Wooding; Richard J Auchus
Journal:  Mol Cell Endocrinol       Date:  2013-01-16       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.